Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort

References

• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380:1590–605.
   PubMed Web of Science ®Google Scholar
• Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606–19.
   PubMed Web of Science ®Google Scholar
• Peake ST, Bernardo D, Mann ER, Al-Hassi HO, Knight SC, Hart AL. Mechanisms of action of anti-tumor necrosis factor α agents in Crohn’s disease. Inflamm Bowel Dis 2013;19:1546–55.
   PubMed Web of Science ®Google Scholar
• Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. Mucosal healing with anti-TNF antibodies. Digestion 2012;86:16–22.
   PubMedGoogle Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med 1997;337:1029–35.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009;337:1029–35.
   Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–33.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829–38.
   PubMed Web of Science ®Google Scholar
• Lawson MM, Thomas AG, Akobeng AK. Tumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112.
   Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate- to-severe ulcerative colitis. Gastroenterology 2012;142:257–65.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:2228–38.
   Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen O, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357:239–50.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen O, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600–9.
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644–59.
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92–101.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Panes J, Beaugerie L, Karagannis J, Allez M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 2010;4:7–27.
   PubMed Web of Science ®Google Scholar
• Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1–23.
   PubMed Web of Science ®Google Scholar
• Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009;38:922–31.
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:5–36.
   PubMed Web of Science ®Google Scholar
• Damas OM, Jahann DA, Reznik R, McCauley JL, Tamariz L, Deshpande AR, et al. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-hispanic whites: results of a large cohort study. Am J Gastroenterol 2013;108:231–9.
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: results from the COIN study. Gut 2014;63:72–9.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ, et al. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease. Aliment Pharmacol Ther 2010;32:384–93.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panes J, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECISE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1572–82.
   Google Scholar
• Ananthakrishnan AN, Binion DG. Editorial: improved efficacy of biological maintenance therapy in “early” compared with “late” Crohn’s disease: strike while the iron is hot with anti-TNF agents? Am J Gastroenterol 2010;105:1583–5.
   PubMedGoogle Scholar
• Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, De Angelis GL, et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 2003;18:425–31.
   PubMed Web of Science ®Google Scholar
• Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn’s disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis 2013;19:1173–8.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz R, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-TNF agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis 2012;18:1523–30.
   PubMed Web of Science ®Google Scholar